Valneva confirms initiation of rolling review with ema and provides updates on its covid-19 vaccine program vla2001

Saint- herb lain (france ) , december 2 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today confirmed that the european medicines agency (ema) has started a rolling review of vla2001, its whole-virus inactivated, adjuvanted covid-19 vaccine candidate.
VALN Ratings Summary
VALN Quant Ranking